CA-ENEVATE
14.1.2020 12:02:06 CET | Business Wire | Press release
Enevate , a pioneer in advanced silicon-dominant lithium-ion (Li-ion) battery technology capable of extreme fast charging for electric vehicles (EVs), announced its new 4th generation technology optimized for high volume commercialization and manufacturing at gigafactory scale. Enevate is providing a solution to a difficult problem for automotive OEMs and EV battery manufacturers – providing extreme fast charging with high energy density and at lower material cost than conventional Li-ion batteries, while being compatible with existing battery fabrication facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200114005035/en/
The new XFC-Energy™ technology achieves 5-minute charging to 75 percent capacity with 800 Wh/L cell energy density. Today’s conventional large-format Li-ion EV cells are at 500-600 Wh/L and typically take over 1 hour to charge.
“Mass EV adoption by consumers and fleet owners will depend to a large degree on advanced battery technology that will remove current barriers to entry such as long charging times and limited range,” said Christian Noske , Chairman of Alliance Ventures (Renault-Nissan-Mitsubishi). “Enevate is a key enabler for electric vehicles that are affordable, easy and quick to charge, and clean.”
Dr. John Goodenough , a recipient of the 2019 Nobel Prize in chemistry for groundbreaking work in the development of lithium-ion batteries and who has served on Enevate’s Advisory Board since 2010, added: “I salute the Enevate team for reaching this next important step in fulfilling the company’s mission to develop and commercialize innovative battery technologies to accelerate the adoption of electrified mobility.”
Enevate’s 4th generation XFC-Energy technology stands to be a game-changer for the EV industry, providing a path to produce extreme fast-charge EV batteries at low cost and high-volume production. Enevate is currently working with multiple automotive OEMs and EV battery manufacturers to commercialize its technology for 2024-2025 model year EVs, utilizing existing manufacturing infrastructure with minimal investment required, a core goal of its development.
Enevate’s 4th generation is the latest result of over 74 million hours of battery cell testing by Enevate’s scientists, 1 million meters of electrodes produced in the company’s R&D pilot line, and 2 billion test datapoints.
Enevate Founder and Chief Technology Officer Dr. Benjamin Park noted that Enevate’s XFC-Energy technology has been designed for large-format pouch, prismatic and cylindrical EV cells, utilizing its pure silicon anode paired with nickel-rich NCA, NCM and NCMA advanced cathodes.
“Enevate’s extreme fast charge technology enables a future where gas stations become drive-through EV charging stations – a win-win for consumers and the environment as electric vehicles replace those using gasoline,” Dr. Park said. “Enevate’s technology will help close the usability gap between today’s EVs and gas cars.”
Dr. Park will be discussing Enevate’s technology on January 15 at the Advanced Automotive Battery Conference in Weisbaden, Germany, in a presentation titled “Charging Ahead: Commercializing Fast-Charge Si-Dominant Li-ion Cells for EVs.”
XFC-Energy Technology Technical Details
- Cell technology scalable for large-format pouch, prismatic and cylindrical EV cells suitable for various battery module and pack architectures. Achieves 800 Wh/L and 340 Wh/kg in large-format EV cells.
- Pure silicon-dominant anode technology tunable with 10-60µm thickness and 1000-2000mAh/g that can be paired with NCA, NCM811, NCMA, low-cobalt, or other advanced cathode technologies.
- Continuous roll-to-roll anode manufacturing processes designed and capable of achieving over 80 meters per minute electrode production, over 10 GWh per electrode production line, with pure silicon anode rolls greater than 1 meter wide and longer than 5 kilometers in length sufficient for high volume gigafactory production, among other features.
- Lower anode material cost (dollar per kWh) than conventional and synthetic graphite.
- Transformative performance improvement, with five-minute charge to 75 percent of battery capacity, and, when paired with a high-nickel cathode, capable of over 1000 cycles using an EV drive cycle test and operation at -20˚C and below temperatures.
- Bottom line: Five-minute extreme fast charging, high energy density, low temperature operation, low cost and superior safety.
ABOUT ENEVATE (www.enevate.com)
Enevate develops and licenses advanced silicon-dominant Li-ion battery technology for electric vehicles (EVs), with a vision to charging EVs as fast as refueling gas cars and accelerating their mass adoption. With a portfolio of more than 200 patents issued and in process, Enevate’s pioneering advancements in silicon-dominant anodes and cells have resulted in battery technology that features five-minute extreme fast charging with high energy density, low temperature operation for cold climates, low cost and safety advantages over conventional Li-ion batteries.
Enevate’s vision is to develop and propagate EV battery technology that contributes to a clean and sustainable environment. The Irvine, California-based company has raised over $110 million from investors including Renault-Nissan-Mitsubishi (Alliance Ventures), LG Chem, Samsung, Mission Ventures, Draper Fisher Jurvetson, Tsing Capital, Infinite Potential Technologies, Presidio Ventures – a Sumitomo Corporation company, Lenovo, CEC Capital and Bangchak. Enevate®, the Enevate logo, XFC-Energy™, HD-Energy®, and eBoost® are registered trademarks of Enevate Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
